Rare Kidney Disease News is a regular newsletter for the nephrology community. We bring awareness and highlight scientific developments in rare kidney disease research with the goal of bettering outcomes for patients.
Thank you for continuing to join us in this educational series.
Sparsentan in IgAN: Spotlight on Phase 2 and OLE Clinical Trial Results Evaluating Concomitant Use With SGLT2i
Explore insights from the Phase 2 SPARTACUS trial, PROTECT OLE, and real-world data evaluating use of sparsentan with SGLT2i in IgAN
Learn More
Engaging Patients for Better Outcomes: Informed Care for IgA Nephropathy
Access IgAN patient education resources, learn more about how IgAN develops, and explore advancements in IgAN care.
Learn More
Exploring Clinical Trial Endpoints in FSGS: Spotlight on Proteinuria
Learn more about proteinuria as a primary clinical trial endpoint for focal segmental glomerulosclerosis studies.
Learn More
Exploring the Mechanism of Sparsentan in IgAN: Including a Spotlight on Urinary sCD163, a Key Marker of Inflammation
Learn more about the role of u-sCD163 in IgAN and the biomarker findings from the SPARTAN interim analysis!
Learn More
ASN 2024 Spotlight: New Treatment Targets in IgA Nephropathy
Learn more about patients on sparsentan achieving updated proteinuria treatment goals outlined in the 2024 KDIGO draft guideline.
Learn MoreMA-DS-24-0051| October 2024